Diabetes, obesity & metabolism

A molecule that first activates then blocks two hormone receptors leads to greater weight loss in obese mice

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Pharmacological agents targeting the GLP-1 and GIP receptors are promising for diabetes and obesity treatment.

  • GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists may effectively aid in weight management.
  • The specific impact of activating versus inhibiting the GIP receptor on weight loss is not yet understood.
  • Current therapies include Semaglutide, Tirzepatide, and AMG133, which show potential in managing diabetes and obesity.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

0 of 11
authors report competing interests
11 report none
PubMed
No competing interests reported.

Related papers

Dec '18
Improved GIP-like drugs reduce body weight in mice by activating, not blocking, GIP receptors
top 5% journal
cited by 225 papers
research support, non-u.s. gov't
Nov '24
Loss of a specific signaling in inhibitory brain cells increases weight loss caused by GLP-1 receptor drugs
top 5% journal
cited by 19 papers
journal article
Apr '26
Combined activation of five hormone receptors improves obesity and diabetes in mice
cited by 11 papers
journal article
Apr '26
Combined activation of two hormone receptors helps obese rodents return to normal weight
top 5% journal
journal article
Nov '22
Identification of a strong peptide blocker of the GIP receptor effective in both rodent and human systems
top 5% journal
cited by 55 papers
research support, non-u.s. gov't
Mar '24
Loss of GIP receptor in leptin receptor cells reduces glucose control by GIP and GIP-GLP-1 combination without changing body weight or food intake in mice
top 5% journal
cited by 13 papers
research support, non-u.s. gov't
May '26
The Challenges and Potential of Combining GLP-1 and GIP Treatments: How They Work and How Well They Help
top 2% journal
journal article
Jun '20
Fast identification of a new drug that activates two hormone receptors to improve blood sugar control and reduce weight in rodents
cited by 6 papers
journal article
Jul '26
Different brain areas control eating when GIP receptors are activated or blocked
top 1% journal
cited by 1 paper
journal article
Aug '26
How GLP-1 and GIP receptor drugs help treat diabetes and obesity
top 5% journal
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
2 weeks ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
3 weeks ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
4 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
5 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
6 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
7 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
8 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
9 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
10 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
11 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief